Ankit Kansagra, MD, an assistant professor in theDepartment of Internal Medicineat UT Southwestern Medical Center and assistant director of theOutpatient Stem Cell Transplant Program, talks about the potential for changes to combination therapy for multiple myeloma (MM) with the approval of chimeric antigen receptor T-cell agents and the introduction of quadruplet therapy.
In part three of this interview with Dr. Kansagra, available December 15, he discusses newly approved therapies for MM and highlights drugs in the pipeline.
DocWire News: Do you foresee combination therapy for multiple myeloma changing in the next few years, and how would this impact the treatment paradigm and potentially guideline-directed care?
Dr. Kansagra: Lets talk about patients with newly diagnosed multiple myeloma. Right now, we know that for the majority of the country, the standard of care is a combination of three different medicationmay it be bortezomib or [carfilzomib], those are the proteasome inhibitors, lenalidomide, and dexamethasone.
There is a huge debate nationally, or internationally, about adding a fourth agent improves things. There are questions about improving response and the durability of response. Can you get the response, first? And can you sustain that response? Those are two different questions. We know most of the therapies, as of today, including the triplet therapies, are able to get a response; its the durability that is an issue, and can they persist for a longer time or getting the patients into minimal residual disease (MRD), or the lowest disease possible.
Some call it measurable residual disease, some call it minimal residual disease. The point that comes up too is, Are we going to a quadruplet therapy? And the answer to that is yes. I think we are going to a quadruplet therapy, but For who? is going to be a point and For how long? When do you increase the intensity of therapy? When you decrease the intensity of therapy? Would MRD be a guide to deciding how those therapies are done? Those are going to be some of the crucial factors in deciding. So I dont think quadruplet is needed for every single individual with newly diagnosed myeloma. There are subsets who will benefit from it, and there are subsets who probably do not need that aggressive treatment.
For combination with CAR-T cells, I think thats probably a more challenging question. The first question is, scientifically, should we combine something to CAR T-cell therapy to improve its response? As I mentioned earlier, CAR T-cell therapies in lymphoma have shown certainly more impressive responses than what we might have expected in myeloma. Having said that, the diseases are completely different; the biology is completely different. We certainly dont want to compare apples and oranges here. But obviously, there is a challenge in front of us: How are we going to have these CAR T-cells persist to be effective for a longer period of time? Obviously, there has been an ongoing debate and also a lot of clinical trials ongoing, which are thinking of adding medications to the CAR T-cell therapy treatment.
And that may be medications like immunomodulatory drugs or proteasome inhibitors. IMiDs or [lenalidomide] or [pomalidomide], those are certainly key targets here to think of. Even checkpoint inhibitors have been used in some clinical trials, like PD-1 or PD-L1 inhibitors in some clinical trials. I think those are another avenue of interest.
The more important question, to me, is what combination to use rather than what are the potential mechanisms of relapse? Why is CAR-T not working for individual A compared to B compared to C? Is it because the cells are not persisting? Is it because they are losing the BCMA expression? Is it because the CAR-Ts are not expanding at all? And the intervention for each bucket is potentially going to be a different intervention. Some might need a BCMA-targeted ongoing therapy after a CAR T-cell therapy. That might be a strategy in one population, whereas other might need just augmentation with an IMiD. Maybe there is a third, who does not need any intervention at all.
Scientifically speaking, as a physician-scientist, I would think an important thing for us to understand is what are these different categories of patients where we would intervene differently and appropriately. If Im talking to my patient as a physician, as a clinician, sitting in the patients room and thinking of the challenges in the healthcare system, we loved CAR T-cell therapy that we dont have to combine with anything. The initial two years, we loved it, that you get CAR T-cell therapy. My patients tell me, Hey doc, I feel like I dont have myeloma at all.
Thats the comment I get very often from my patients who have received CAR T-cell therapy. The majority of these guys have got stem cell transplant before and have been on maintenance therapies and some ongoing treatment. When it comes to us doing some combination along with CAR T-cell therapy, that is certainly a bummer from them saying, Hey, this was kind of one of those hopes, where we would have done a one-time thing and it would work forever.
From the patients perspective, from a healthcare cost perspective, from a physician sitting in front of them and trying to think what is the easiest in their patient-reported outcome standpoint, Im not too excited about combining things, but I suppose that it is going toward that way to get the best efficacy. So I think rather than saying, Everybody should get a maintenance therapy, like we do for transplant for a big chunk of our patients or pretty much everybody in the United States, I think we will have to think of a much more scientifically-driven answer about who benefits from it.
Watch part 1 of the interview with Dr. Kansagra where he discusses CAR T-cells in development for MM.
View original post here:
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
Recent Comments